Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIST II: Adjuvant TS-1 vs TS-1 + oxaliplatin ± radiotherapy in resected gastric adenocarcinoma
KCT0003993Phase 3Recruiting
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Feb 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur and oxaliplatin in gastric adenocarcinoma (3 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Started Feb 2013; status: recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0003993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003993.